Arbaclofen placarbil (AP):
May be effective in reducing spasticity with fewer doses. The ongoing study is funded by XenoPort, Inc.
Phase 3 Trial for Alemtuzumab
Phase 3 trial of Alemtuzumab versus interferon beata-1a seems to be positive with significant reduction in relapses in patients taking this agent versus Rebif.
Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis I (CARE-MS I) trial were presented at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS/ACTRIMS). This substance helps block the effect and number of two blood cell types called the monocytes and lymphocytes thereby reducing multiple sclerosis attacks.